Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3560 - Fully automated and sensitive detection of EGFR exon 18, 19, 20 and 21 mutational status in less than 2.5 hours from a single FFPE slice

Date

10 Oct 2016

Session

Poster display

Presenters

Martin Reijans

Citation

Annals of Oncology (2016) 27 (6): 401-406. 10.1093/annonc/mdw380

Authors

M. Reijans1, G. Vandercruyssen1, I. Keuleers1, C. Vandesteene1, I. Vandenbroucke2, G. Maertens1, E. Sablon1

Author affiliations

  • 1 -, Biocartis, 2800 - Mechelen/BE
  • 2 -, Multiplicom, Niel/BE
More

Resources

Abstract 3560

Background

Current testing for mutations, insertions and deletions in EGFR exons 18, 19, 20, and 21 is still laborious and often requires >5 working days and multiple slices of formalin-fixed paraffin-embedded (FFPE) tissue. Lack of time or tissue for molecular testing are among the main reasons why patients are often deprived of the proper targeted therapies.

Methods

Idylla is a fully integrated and automated molecular diagnostics platform that combines speed and ease of use with high sensitivity and high multiplexing capabilities. Moreover, it overcomes the current problem of lack of tissue, and the time-consuming step of processing FFPE tissue samples. After insertion of a single FFPE slice into the cartridge, the complete process of sample liquefaction, nucleic acid preparation, real-time PCR, data analysis, and reporting is fully automated and takes less than 2.5 hours. The Idylla EGFR prototype assay allows the sensitive detection of 53 mutations including insertions and deletions in exons 18, 19, 20 and 21.

Results

Sensitivity was assessed for 20 mutations using cell line derived materials embedded in paraffin containing defined ratios of mutants and dilutions thereof in a WT background. Allelic frequencies ranging from 1 to 50% were tested in triplicate and showed analytical sensitivities of ≤1% up to ≤5% for all targets. The Idylla EGFR prototype assay was also tested with single FFPE slices from 141 clinical NSCLC samples with known mutations as analyzed by NGS and digital droplet PCR. It demonstrated excellent clinical specificity and sensitivity with a negative percentage agreement of 100% and an overall percentage agreement of 96.3%.

Conclusions

The new and fully automated Idylla EGFR prototype assay demonstrates excellent specificity, high sensitivity, ease of use combined with a fast turnaround time for complete EGFR testing on FFPE samples from NSCLC patients.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Biocartis

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings